Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00766571
Other study ID # 080224
Secondary ID 08-HG-0224
Status Completed
Phase
First received
Last updated
Start date September 29, 2008
Est. completion date June 29, 2017

Study information

Verified date June 29, 2017
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will explore the medical problems in patients with VACTERL association and identify gene changes that might be responsible for them. VACTERL association can affect many parts of the body, including the bones of the spine, the heart, the lower intestinal tract, the connection between the trachea and esophagus, the kidneys and the arms. Information from this study may lead to a better understanding of the disease and improved treatment and genetic counseling.

Patients with VACTERL association and their parents and siblings may be eligible for this study.

Patients are admitted to the NIH Clinical Center for evaluation over 3 to 4 days that may include the following procedures:

- Physical examination, medical history, electrocardiogram (EKG), blood and urine tests

- Eye examination

- Imaging studies (echocardiogram, x-rays and ultrasound tests)

- Other specialized tests or consultations as indicated

- Optional medical photographs of the face and other body parts that may be involved in VACTERL association for publication in scientific texts or for teaching purposes

- Optional return visit after 2 years for repeat testing and to look for changes over time

Parents of patients have the following procedures:

- Physical examination, medical history, blood tests and x-rays, if needed

- Specialty consultations as indicated

- Optional medical photographs of the face and other body parts that may be involved in VACTERL association for publication in scientific texts or for teaching purposes

- Questionnaires about their child s medical history, growth, behavior and development, therapy and medication

Siblings of patients have the following procedures:

- Physical examination, medical history and blood tests


Description:

The combination of vertebral defects, anal atresia, cardiac anomalies, tracheo-esophageal fistula, radial dysplasia and limb anomalies, and renal anomalies, termed VACTERL association, has been used as a clinical descriptor for a specific group of phenotypic manifestations that have been observed to occur together. Depending upon the diagnostic criteria used, the prevalence may be as high as 1 in 6000 live births. VACTERL association is felt to be due to defects in early embryogenesis, and is likely to be genetically heterogeneous. The purpose of the present study is to increase the understanding of the clinical manifestations and genetic causes of VACTERL association through detailed physical, laboratory, and radiological studies. We also plan to examine the spectrum of clinical characteristics in VACTERL association to facilitate early diagnosis and clinical management, including genetic counseling. To accomplish this, we plan to enroll approximately 25-50affected individuals along with their family members for a total of 75-150 total individuals each year, with an enrollment ceiling of 500 affected individuals. Patients and their families will be seen at the NIH clinical center.


Recruitment information / eligibility

Status Completed
Enrollment 304
Est. completion date June 29, 2017
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group N/A to 100 Years
Eligibility - INCLUSION CRITERIA:

(A) For affected individuals, determination of clinical criteria for inclusion will be determined by prior medical record review before participation. Inclusion criteria may be met in 1 of 3 ways:

1. At least 3 features of VACTERL association in an index case OR

2. Two features of VACTERL association in an index case plus at least 1 feature of VACTERL association in a relative OR

3. At least 2 features of VACTERL association in an index case plus at least 1 other anomaly.

(B) First degree relatives (parents and/or siblings of affected individuals) of patients with VACTERL association are also eligible to participate in portions of the protocol even if they have no features of VACTERL association.

EXCLUSION CRITERIA:

1. Anyone unwilling to provide informed consent (for themselves as adults, or on behalf of their children as minors, or on behalf of an adult who is unable to provide consent for themselves) or assent.

2. Cases that are clearly not in the spectrum of VACTERL association or related to our direct research interests (e.g. referred VACTERL cases that are felt to be related to other syndromes, such as Feingold syndrome, Townes-Brocks syndrome, or Pallister-Hall syndrome, would not be included). In such instances, we would attempt to make referrals to a more appropriate investigator.

Study Design


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Arsic D, Beasley SW, Sullivan MJ. Switched-on Sonic hedgehog: a gene whose activity extends beyond fetal development--to oncogenesis. J Paediatr Child Health. 2007 Jun;43(6):421-3. Review. — View Citation

Arsic D, Qi BQ, Beasley SW. Hedgehog in the human: a possible explanation for the VATER association. J Paediatr Child Health. 2002 Apr;38(2):117-21. Review. — View Citation

Botto LD, Khoury MJ, Mastroiacovo P, Castilla EE, Moore CA, Skjaerven R, Mutchinick OM, Borman B, Cocchi G, Czeizel AE, Goujard J, Irgens LM, Lancaster PA, Martínez-Frías ML, Merlob P, Ruusinen A, Stoll C, Sumiyoshi Y. The spectrum of congenital anomalies of the VATER association: an international study. Am J Med Genet. 1997 Jul 11;71(1):8-15. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05883761 - Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
Recruiting NCT05394363 - Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents
Not yet recruiting NCT05393167 - Congenital Anomalies in Infants of Diabetic Mother
Not yet recruiting NCT05547308 - Evaluation of 3D Printed Myoelectric Prosthetic Devices in Children With Upper Congenital Limb Deficiency N/A
Recruiting NCT05151042 - Digital Occlusal Wafer Versus Waferless Distal Segment Repositioning for BSSO in Skeletal Mandibular Deformities N/A
Recruiting NCT05738954 - Pattern Recognition and Anomaly Detection in Fetal Morphology Using Deep Learning and Statistical Learning
Recruiting NCT02505464 - Pregnancies Complicated by Fetal Anomalies
Recruiting NCT02595307 - Improving Informed Consent for Cleft Palate Repair N/A
Completed NCT00477594 - Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Phase 2
Completed NCT00062452 - Esophageal Motility and Airway Defenses Among Infants N/A
Recruiting NCT05763615 - 3D Modeling of the Cervico-facial Region and Cranial Nerve Tractography: IMAG 2 ORL Project N/A
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Recruiting NCT04591392 - Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD N/A
Not yet recruiting NCT05231447 - Birth Defect Registry in South West Region of France
Completed NCT01653392 - BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Completed NCT02429947 - An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients N/A
Completed NCT00607373 - Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Phase 3
Completed NCT00362180 - Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Phase 2
Active, not recruiting NCT02987387 - COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
Completed NCT02875860 - 'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial Phase 2